...
首页> 外文期刊>Journal of Cancer >Cisplatin based induction chemotherapy modified by ERCC1 improved the outcome of young adults with locally advanced oral squamous cell carcinoma
【24h】

Cisplatin based induction chemotherapy modified by ERCC1 improved the outcome of young adults with locally advanced oral squamous cell carcinoma

机译:ERCC1修饰的基于顺铂的诱导化疗改善了局部晚期口腔鳞状细胞癌的年轻人的疗效

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: To evaluate the efficacy of induction chemotherapy in young adults with locally advanced oral squamous cell carcinoma (OSCC) and the usefulness of ERCC1 as a prognostic indicator. Methods: A total of 156 young adults with locally advanced OSCC were retrospectively analyzed from May 2007 to May 2017. Cisplatin based induction chemotherapy followed by surgery and upfront surgery were the primary treatment options for locally advanced OSCC. ERCC1 was evaluated by immunohistochemistry. Multivariate analysis was performed to identify significant prognostic factors for the overall survival (OS) in young adults with locally advanced OSCC. Results: Extracapsular spread (ECS) ( p 0.0001) and UICC staging ( p 0.0001) were critical prognostic factors for OS in young adults with locally advanced OSCC. The 5-year OS was 83.2% in N0 patients received induction chemotherapy and 61.7% in N0 patients received upfront surgery ( p 0.05). Patients with a low ERCC1 expression were more likely to benefit from induction chemotherapy, as the 5-year OS was 22.4% in patients with a high ERCC1 expression and 84.7% in patients with a low ERCC1 expression, respectively ( p 0.0001). However, induction chemotherapy resulted in a higher 5-year OS (84.7%) than upfront surgery (59.1%) in patients with a low ERCC1 expression ( p =0.03). Conclusions: Induction chemotherapy can improve the outcome of N0 patients. However, the ERCC1 expression should be determined in young patients with locally advanced OSCC prior to induction chemotherapy, as it is a useful biomarker for predicting the outcome after induction chemotherapy.
机译:目的:评价诱导化学疗法在年轻成人局部晚期口腔鳞状细胞癌(OSCC)中的疗效以及ERCC1作为预后指标的有用性。方法:回顾性分析了2007年5月至2017年5月的156例局部晚期OSCC的年轻人。以顺铂为基础的诱导化疗,然后进行手术和前期手术是局部晚期OSCC的主要治疗选择。通过免疫组织化学评估ERCC1。进行多变量分析,以鉴定患有局部晚期OSCC的年轻成年人的总生存期(OS)的重要预后因素。结果:囊外扩散(ECS)(p <0.0001)和UICC分期(p <0.0001)是患有局部晚期OSCC的年轻成年人OS的重要预后因素。接受诱导化疗的N0患者的5年OS为83.2%,接受前期手术的N0患者的5年OS为61.7%(p <0.05)。 ERCC1表达低的患者更有可能受益于诱导化疗,因为ERCC1表达高的患者的5年OS分别为22.4%,ERCC1表达低的患者的84.7%(p <0.0001)。然而,对于ERCC1表达低的患者,诱导化疗导致的5年OS(84.7%)比前期手术(59.1%)高(p = 0.03)。结论:诱导化疗可改善N0患者的预后。但是,ERCC1表达应在诱导化疗之前局部晚期OSCC的年轻患者中测定,因为它是预测诱导化疗后结果的有用生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号